Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
3.
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Lancet
; 398(10306): 1157-1169, 2021 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34508654
4.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141632
5.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(6): 801-812, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34087126
6.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
7.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
8.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
9.
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
Immunol Rev
; 270(1): 95-112, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26864107
10.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 375(8): 754-66, 2016 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27557302
11.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 375(14): 1319-1331, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27705267
12.
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Blood
; 130(8): 974-981, 2017 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28637662
13.
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
N Engl J Med
; 373(13): 1207-19, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26308596
14.
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Blood
; 128(1): 37-44, 2016 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27216216
15.
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Blood
; 128(3): 384-94, 2016 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27222480
16.
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Blood
; 128(14): 1821-1828, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27531679
17.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lancet
; 387(10027): 1551-1560, 2016 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26778538
18.
Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
Oncologist
; 21(11): 1355-1361, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27486203
19.
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
Clin Chem Lab Med
; 54(6): 1095-104, 2016 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27028734
20.
When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.
Transfusion
; 55(6 Pt 2): 1555-62, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25988285